Welcome to our dedicated page for Dermata Therapeutics SEC filings (Ticker: DRMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dermata Therapeutics, Inc. filings document a dermatology-focused operating company with common stock and publicly traded warrants, a direct-to-consumer skincare strategy and ongoing capital-structure activity. Recent Form 8-K reports cover annual and quarterly operating results, prospectus supplements for at-the-market common stock sales, private financing-related disclosure, and material agreements tied to the company's shift away from pharmaceutical development.
Dermata's proxy and governance filings address shareholder voting matters, board composition and corporate governance. Other current reports document changes in the independent registered public accounting firm, director resignation disclosures, going-concern context in auditor reports, and material-agreement disclosure involving the Villani license and the XYNGARI investigational new drug application.
Dermata Therapeutics, Inc. (DRMA) reported that director and executive officer Gerald T. Proehl, through affiliated entities, acquired multiple warrant positions and common shares in a private placement exempt under Rule 16b-3(d)(1). Proehl Investment Ventures LLC received 1,360,544 Series E and 1,360,544 Series F warrants and 1,360,544 pre-funded warrants, each for common stock at exercise prices of $1.47 (Series E/F) and $0.001 (pre-funded). A family trust acquired 170,068 Series E, 170,068 Series F warrants and 170,068 common shares, increasing its indirect holdings to 292,631 shares. The warrants become exercisable only after stockholder approval and are subject to a 9.99% beneficial ownership cap, and the reporting person disclaims beneficial ownership beyond pecuniary interest.
Dermata Therapeutics, Inc. (DRMA) reported that its SVP and CFO, Kyri K. Van Hoose, acquired securities in a private placement. She acquired 102,040 shares of common stock and now directly holds 232,463 common shares. In the same transaction, she received a Series E Warrant and a Series F Warrant, each for 102,040 underlying common shares at an exercise price of $1.47 per share. The common stock and accompanying warrants were purchased together at $1.47 per unit. The warrants become exercisable on the effective date of required stockholder approval, are capped at 9.99% beneficial ownership, and expire five years (Series E) and two years (Series F) after that approval.
Dermata Therapeutics, Inc. is having its warrant class removed from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq states it has complied with its own rules to strike this class of securities, and the company has complied with exchange rules and SEC requirements governing voluntary withdrawal.
Dermata Therapeutics, Inc. entered into securities purchase agreements for a private placement of an aggregate of 2,293,608 shares of common stock (or pre-funded warrants in lieu thereof), plus accompanying Series E and short-term Series F warrants, at $1.46 per share (or pre-funded warrant) and accompanying warrants. The transaction is expected to generate gross proceeds of approximately $3.4 million and net proceeds of about $3.2 million, with up to approximately $6.7 million of additional gross proceeds if all Series E and Series F warrants are exercised for cash. Company insiders, including the CEO and CFO, are participating at $1.47 per share (or pre-funded warrant) and accompanying warrants for about $2.4 million. The warrants become exercisable upon stockholder approval, with Series E expiring five years and Series F expiring twenty-four months after that approval. Dermata plans to use the proceeds for general corporate purposes, including launch and marketing of its new direct-to-consumer skincare products and potential acquisitions or licensing opportunities.
Dermata Therapeutics, Inc. reports continued pre-revenue operations for the quarter and six months ended June 30, 2026, as it pivots from prescription dermatology to direct-to-consumer Tome skincare, targeting an initial product launch on August 25, 2026. Total assets were $5.3 million, including $4.4 million of cash and cash equivalents, down from $7.9 million and $7.5 million at December 31, 2025. Stockholders’ equity declined to $3.5 million as accumulated deficit grew to $78.0 million.
For the three and six months ended June 30, 2026, Dermata recorded net losses of $2.97 million and $4.81 million, compared with $1.70 million and $4.00 million in the prior-year periods, driven mainly by higher selling, general and administrative expenses of $2.80 million and $4.34 million as the company invests in compliance, marketing, and commercial readiness. Net cash used in operating activities was $4.90 million for the first half of 2026, partially offset by $1.99 million of ATM equity proceeds, resulting in a cash burn that management expects will fund operations only into the fourth quarter of 2026.
The company explicitly states that recurring losses, negative operating cash flows, and limited cash resources raise substantial doubt about its ability to continue as a going concern for one year from issuance of these financial statements. Management plans to rely on additional equity or debt financings and future product revenues, but acknowledges no assurance such capital will be available on favorable terms, if at all. Risks include heavy dependence on a single Russian supplier for Spongilla raw material, significant warrant and potential equity overhang, related-party marketing spend, and ongoing litigation and arbitration with former licensor Villani that could result in injunctive relief or money damages and adversely affect operations.
Dermata Therapeutics reported second quarter 2026 results and detailed its pivot to a commercial-stage, direct-to-consumer skincare model centered on its Tome™ line. The company plans to launch its first product, Tome Foundational Treatment, on August 25, 2026, aiming to begin generating product revenue.
For the quarter ended June 30, 2026, Dermata reported a net loss of $2.97 million, compared with $1.70 million a year earlier, as selling, general and administrative expenses rose to $2.80 million from $1.16 million, driven by higher legal, marketing, commercialization, and employee costs. Research and development expenses declined to $0.21 million from $0.62 million as resources were reallocated toward commercialization. Cash and cash equivalents were $4.4 million as of June 30, 2026, versus $7.5 million at year-end 2025, and the company expects its current cash to fund operations into the fourth quarter of 2026.
Dermata Therapeutics, Inc. disclosed that its first commercial product, the Tome Foundational Treatment, is expected to launch soon. The company expects the Foundational Treatment to be available for sale starting August 25, 2026, with customers on a waitlist receiving early access to preorder.
The Foundational Treatment set comprises four once-weekly treatments, sold exclusively through www.tomeskincare.com for $178, described as about $45 per treatment. The company also includes forward-looking statements about a strategic shift to commercialize skincare products and potential benefits such as accelerating commercialization, reducing regulatory burdens, and expanding into broader consumer markets, subject to risks outlined in its SEC reports.
Dermata Therapeutics director Kathleen D. Scott reported a small open-market sale of common stock. She sold 11 shares of Dermata Therapeutics, Inc. common stock in an open-market transaction at a price of $1.1901 per share. After this sale, she held no shares directly but reported indirect ownership of 1 share held by the Scott 2008 Trust Dated 3/28/08.
Kyri K. Van Hoose, Chief Financial Officer of Dermata Therapeutics, Inc., filed a Schedule 13D reporting a significant equity stake in the company. As of May 27, 2026, she may be deemed to beneficially own 384,352 shares of common stock, representing 9.0% of Dermata’s 4,022,143 shares outstanding.
Her position consists of 130,423 common shares, warrants exercisable for 252,972 shares, and stock options exercisable for 957 shares, with additional options excluded because they are not exercisable within 60 days. A large portion of this stake stems from a December 23, 2025 private placement, where she purchased common stock and warrants on the same terms as institutional and accredited investors, mainly for investment purposes while reserving flexibility to change her holdings over time.